Spinogenix
Clinical trials sponsored by Spinogenix, explained in plain language.
-
Alzheimer's drug trial cut short: SPG302 long-term study terminated
Disease control TerminatedThis study aimed to see if taking SPG302 daily for a long time is safe and helps slow Alzheimer's in people with mild-to-moderate symptoms. It included 12 adults who had already been in an earlier SPG302 study. The trial was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Spinogenix • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
ALS drug trial stopped early: what happened with SPG302?
Disease control TerminatedThis study looked at the long-term safety of a daily pill called SPG302 for people with amyotrophic lateral sclerosis (ALS). It included 16 participants who had already taken part in an earlier SPG302 study. The trial was terminated early, and researchers focused on tracking side…
Phase: PHASE2 • Sponsor: Spinogenix • Aim: Disease control
Last updated May 07, 2026 18:39 UTC